Trinity Biotech Secures 2M HIV Test Orders, Reports Q1 2026 Margin Gains
Event summary
- Trinity Biotech received orders for 2M TrinScreen HIV tests, scheduled for Q3 2026 delivery.
- Q1 2026 revenue rose 43% YoY to $10.8M, with gross margin improving to 35.4% from 25.2%.
- UniGold HIV production scale-up expected to complete by Q3 2026 under outsourced manufacturing model.
- Net loss narrowed to $4.4M from $8.8M YoY, with adjusted EBITDA improving to -$1.1M from -$4.0M.
The big picture
Trinity Biotech's strong Q1 2026 results and significant HIV test orders reflect renewed demand in global health markets following 2025 funding disruptions. The company's Comprehensive Transformation Plan, focusing on outsourced manufacturing, appears to be delivering cost efficiencies and margin improvements. The strategic shift towards wearable biosensors through the Waveform Technologies acquisition positions Trinity Biotech for long-term growth in diabetes management.
What we're watching
- Manufacturing Execution
- Whether Trinity Biotech can successfully scale UniGold HIV production under the outsourced model by Q3 2026.
- Market Demand
- How sustained global health market demand will impact future HIV test orders.
- Profitability Trends
- The pace at which gross margin improvements translate into positive EBITDA.
Related topics